Hey Market Enthusiast,
 

Today’s been a whirlwind for Synaptogenix, Inc. (Nasdaq: SNPX)! The stock has been buzzing with interest, and the volume today is absolutely smashing its 30-day average. Hitting a high of nearly $4.10, up from yesterday’s close of $3.53, SNPX has everyone asking: Are we going to see a final surge and an exciting finish to the day? (5)(6)
 

With all the recent developments – from key partnerships to fresh FDA approvals – it’s no surprise that SNPX is grabbing attention. The momentum is real, and if today’s action is any indication, this could be just the beginning of something big. The energy around this stock is palpable, and now’s the perfect time to keep a close watch.

(7)

This company is partnering with top-tier institutions, securing key FDA approvals, and building serious momentum in the biotech space. Analysts are already buzzing about the massive potential here, and we think you’ll want to take a closer look. This isn’t just any update – it’s the kind of news that could have a major impact on the future of neurodegenerative treatment. Let’s dive into the details!

Here’s what’s going on:
 

🧠 New Partnership with LSU Health New Orleans: Synaptogenix has teamed up with the Neuroscience Center of Excellence at LSU Health New Orleans. They’re diving into groundbreaking research with their unique polyunsaturated fatty acid (PUFA) analogs to see how they can help treat spinal cord injuries. This could be a huge step forward in treating these and other neurodegenerative diseases. (1)

🏆 FDA Green Light for MS Clinical Trial: The FDA just gave the thumbs-up for Synaptogenix to kick off a new clinical trial with Bryostatin-1, their leading drug candidate, aimed at treating multiple sclerosis (MS). This trial is being led by the Cleveland Clinic’s Mellen Center for Multiple Sclerosis and will use some pretty cutting-edge MRI tech to see how well the drug works on brain health and cognitive function. (2)

📊 Analysts Are Buzzing – 300% Potential Upside: There’s a lot of excitement around Synaptogenix right now, with analysts talking about a potential 300% upside. The company’s low float and strong financial position make it one to watch closely as they continue to push boundaries in their field. (2)(4)(5)

🌳 Five Years of Consistent Growth: Synaptogenix has been steadily growing at over 15% per year for the last five years, all thanks to their relentless focus on developing new therapies for neurodegenerative disorders.(4)(5)(6)
 

So, why is this such a big deal? These latest developments could be game-changers in the fight against diseases like Alzheimer’s, multiple sclerosis, and spinal cord injuries. With their innovative approach and top-tier partnerships, Synaptogenix is positioning itself at the forefront of neurodegenerative treatment research.
 

I’m excited to see where Synaptogenix, Inc. (Nasdaq: SNPX) goes from here, and I think you will be too. 

Keep an eye on this one – there’s a lot more to come!

‼️ ATTENTION ‼️ 

We’re moving to a new WhatsApp Community! Stay in the loop with Market Tips by joining us at the link below:

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://finance.yahoo.com/news/synaptogenix-announces-collaboration-lsu-health-130000005.html

2. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-snpx/synaptogenix
3. https://finance.yahoo.com/news/synaptogenix-announces-fda-authorization-ind-130000758.html
4. https://www.tipranks.com/stocks/snpx/forecast

5. https://finance.yahoo.com/quote/SNPX/

6. https://finance.yahoo.com/quote/SNPX/key-statistics/

7. https://www.synaptogen.com/

8. https://ir.synaptogen.com/assets/uploads/2021/03/Synaptogenix-Corporate-Deck.pdf

Data is provided from third-party sources and Market Tips is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc.laim.er here. 

Momentum Media LLC has not been compensated for today’s profile (Nasdaq: SNPX) and we own zero shares of (Nasdaq: SNPX).